Top

Published in:

01-10-2011 | Letter to the Editor

Dissociation of ferritin and hepcidin in a case of adult-onset Still’s disease

Authors: Hannah Tharmalingam, Damien R. Ashby, Mark Busbridge, Candice Roufosse, Tom D. Cairns

Published in: International Journal of Hematology | Issue 4/2011

Excerpt

Circulating levels of the iron regulatory hormone hepcidin have been shown to be strongly correlated with ferritin in many studies [1‐3]. In a case of adult-onset Still’s disease (AOSD) with striking hyperferritinaemia, we found normal plasma hepcidin suggesting distinct mechanisms of regulation. …

Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to EPO therapy in renal disease. Kidney Int. 2009;75:976–81.CrossRefPubMed

Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for serum hepcidin. Blood. 2008;112:4292–7.CrossRefPubMed

Tomosugi N, Kawabata H, Wakatabe R, et al. Detection of serum hepcidin in renal failure and inflammation using ProteinChip system. Blood. 2006;108:1381–7.CrossRefPubMed

Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.PubMed

Kirino Y, Takeno M, Iwasaki M, et al. Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still’s disease: use in the differential diagnosis of hyperferritinaemia. Arthritis Res Ther. 2005;7:R616–24.CrossRefPubMedPubMedCentral

Title: Dissociation of ferritin and hepcidin in a case of adult-onset Still’s disease
Authors: Hannah Tharmalingam
Damien R. Ashby
Mark Busbridge
Candice Roufosse
Tom D. Cairns
Publication date: 01-10-2011
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 4/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-011-0926-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2011

Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents

An evaluation of peripherally inserted central venous catheters for children with cancer requiring long-term venous access

Attractive tools for systematic case accumulation

Empty sella/pituitary atrophy and endocrine impairments as a consequence of radiation and chemotherapy in long-term survivors of childhood leukemia

Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy

Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement

Keynote webinar | Spotlight on antibody–drug conjugates in cancer